| Literature DB >> 30300371 |
Hanneke Stam1, Johannes C van der Wouden1, Jacqueline G Hugtenburg2, Jos W R Twisk3, Henriëtte E van der Horst1, Otto R Maarsingh1.
Abstract
OBJECTIVES: Dizziness is common in older people. Physicians are often unable to identify a specific cause for dizziness in older people, even after an extensive diagnostic work-up. A prognosis-oriented approach, i.e. treating modifiable risk factors for an unfavourable course of dizziness, may reduce dizziness-related impairment in older people in primary care.Entities:
Mesh:
Year: 2018 PMID: 30300371 PMCID: PMC6178383 DOI: 10.1371/journal.pone.0204876
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow of study participants.
Abbreviations: DHI Dizziness Handicap Inventory; pharm fall risk increasing drug medication adjustment; SMHC stepped mental health care; physio exercise therapy. a at risk: usage of ≥ 3 Fall-risk-increasing drugs and/or presence of depressive or anxiety disorder and/or impaired functional mobility. b does not add up to 83: 7 patients did not start any intervention, 8 patients refused 1 intervention but started 1 or 2 other interventions. c does not add up to 76: 61 patients started 1 intervention, 13 patients started 2 interventions, 2 patients started 3 interventions. d does not add up to 17: 5 patients declined 1 intervention, 2 patients declined 2 interventions, 8 patients declined 1 intervention but started ≥1 other interventions.
Patient characteristics measured at baseline.*.
| Intervention group | Control group | ||
|---|---|---|---|
| Women | 58 (69.9) | 57 (67.1) | |
| Age (years), mean ±SD (range 65–96) | 78.6 ±7.0 | 79.0 ±7.6 | |
| Ethnicity | |||
| Dutch native | 67 (80.7) | 63 (74.1) | |
| Western immigrant | 6 (7.2) | 15 (17.6) | |
| Non-Western immigrant | 10 (12.0) | 7 (8.2) | |
| Level of education | |||
| Elementary school | 14 (16.9) | 9 (10.6) | |
| High school | 49 (59.0) | 58 (68.2) | |
| College/university | 20 (24.1) | 18 (21.2) | |
| Living situation | |||
| Alone | 64 (77.1) | 53 (62.4) | |
| Together | 19 (22.9) | 32 (37.6) | |
| Cardiovascular disease | 72 (86.7) | 74 (87.1) | |
| Neurological disease | 34 (41.0) | 28 (32.9) | |
| Psychiatric disease | 28 (34.1) | 30 (35.3) | |
| Presence of depressive disorder | 11 (13.4) | 7 (8.2) | |
| Presence of anxiety disorder | 24 (29.3) | 23 (27.1) | |
| Presence of panic disorder | 4 (4.9) | 8 (9.4) | |
| Diabetes mellitus | 21 (25.3) | 22 (25.9) | |
| Number of chronic diseases, mean ±SD (range 0–6) | 2.4 ±1.4 | 2.5 ±1.4 | |
| Impaired functional mobility | 21 (25.3) | 25 (29.4) | |
| Falling ≥1 time last year | 43 (51.8) | 46 (54.1) | |
| EQ-5D-5L utility, mean ±SD (range -0.34–1.00) | 0.0.59 ±0.0.26 | 0.66 ±0.22 | |
| EQ-5D-5L VAS, mean ±SD (range 20–95) | 63.8 ±14.7 | 64.8 ±16.2 | |
| DHI score, mean ±SD (range 30–88) | 53.8 ±15.4 | 48.2 ±14.4 | |
| Onset of dizziness | |||
| 1–4 weeks | 1 (1.2) | 2 (2.4) | |
| 1–6 months | 11 (13.3) | 12 (14.1) | |
| 6–48 months | 15 (18.1) | 25 (29.4) | |
| 2–10 years | 42 (50.6) | 31 (36.5) | |
| > 10 years | 14 (16.9) | 15 (17.6) | |
| Description of dizziness | |||
| Instability or unsteadiness | 68 (81.9) | 65 (76.5) | |
| Loss of balance | 70 (84.3) | 68 (80.0) | |
| Light-headedness | 71 (85.5) | 58 (68.2) | |
| Rotational sensation | 63 (75.9) | 58 (68.2) | |
| Tendency to fall | 56 (67.5) | 58 (68.2) | |
| Giddy | 45 (54.2) | 48 (56.5) | |
| Environment spinning | 30 (36.1) | 40 (47.1) | |
| Becoming unwell | 31 (37.3) | 26 (30.6) | |
| Near faint | 20 (24.1) | 23 (27.1) | |
| Everything turning black | 17 (20.5) | 23 (27.1) | |
| No of drugs, mean ±SD (range 0–17) | 7.2 ±3.5 | 7.6 ±3.4 | |
| Polypharmacy | 61 (73.5) | 73 (85.9) | |
| Number of FRIDs, mean ±SD (range 0–10) | 3.2 ±1.8 | 3.5 ±2.0 | |
| ≥ 3 FRIDs | 59 (71.1) | 62 (72.9) | |
* Figures are numbers (percentages) unless stated otherwise.
Abbreviations: SD standard deviation; EQ-5D-5L Euro Quality of Life–5-dimension, 5-level questionnaire
IQR inter quartile range; VAS visual analogue scale; FRIDs Fall-risk-increasing drugs
a Some patients had more than one psychiatric disorder
b Adds up to more than 100%, because more than 1 answer was possible
Fig 2Uptake of and adherence to the interventions.
Fig 3Twelve-month course of dizziness-related impairment as measured with the Dizziness Handicap Inventory (DHI).
Overall intervention effects.
| Intention to treat analysis | Per protocol analysis | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Crude | Adjusted | Crude | Adjusted | |||||||
| DHI score (0–100) | 150 | -0.69 (-5.66; 4.28) | 0.79 | 0.65 (-3.97; 5.27) | 0.78 | 126 | -2.74 (-8.31; 2.84) | 0.34 | -1.39 (-6.64; 3.85) | 0.60 |
| Dizziness frequency (0–45) | 84 | -0.26 (-0.84; 0.32) | 0.38 | -0.32 (-0.91; 0.28) | 0.30 | 71 | -0.17 (-0.78; 0.45) | 0.60 | -0.21 (-0.91; 0.50) | 0.57 |
| Quality of life, VAS (0–100) | 140 | -2.09 (-6.37; 2.18) | 0.34 | -1.23 (-5.60; 3.25) | 0.58 | 117 | -1.43 (-6.21; 3.36) | 0.56 | -0.60 (-5.62; 4.42) | 0.82 |
| Quality of life, utility (-0.29–1.00) | 141 | 0.00 (-0.05; 0.06) | 0.94 | -0.01 (-0.06; 0.04) | 0.60 | 118 | 0.00 (-0.05; 0.06) | 0.88 | -0.02 (-0.07; 0.04) | 0.56 |
| Number of FRIDs (0–10) | 141 | -0.48 (-0.89;-0.06) | -0.57 (-1.01;-0.15) | 119 | -0.53 (-1.00;-0.06) | -0.67 (-1.18;-0.16) | ||||
| Fall frequency | 83 | 1.47 (0.55; 3.89) | 0.44 | 1.07 (0.54; 2.14) | 0.84 | 70 | 1.78 (0.58; 5.43) | 0.31 | 1.15 (0.54; 2.44) | 0.72 |
| Anxiety and depressive disorder | 149 | 1.49 (0.76; 2.92) | 0.25 | 1.49 (0.73; 3.08) | 0.28 | 125 | 1.73 (0.80; 3.71) | 0.16 | 1.74 (0.74; 4.10) | 0.20 |
N: number of respondents in the analyses; CI: confidence interval; DHI: Dizziness Handicap Inventory; VAS: visual analogue scale; FRID: fall risk increasing drug; OR: odds ratio
a Multilevel linear regression
b Negative binomial regression
c Generalized estimating equation (GEE) logistic regression
* Adjusted for age, sex, living alone, polypharmacy, dizziness onset, dizziness-related impairment, number of comorbidities, anxiety and depressive disorder, cardiovascular disease and functional mobility
Intervention effects at 3, 6 and 12 months follow-up (intention to treat).
| 3 months | 6 months | 12 months | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Crude | Adjusted | Crude | Adjusted | Crude | Adjusted | |||||||
| DHI score (0–100) | -0.04 (-2.70; 4.57) | 0.62 | 1.57 (-3.93; 7.08) | 0.57 | -1.03 (-6.81; 4.76) | 0.73 | 0.64 (-4.47; 2.83) | 0.66 | -1.05 (-6.86; 4.77) | 0.72 | -0.31 (-5.84; 5.22) | 0.91 |
| Quality of life, VAS (0–100) | NA | NA | -3.15 (-8.55; 2.25) | 0.25 | -2.49 (-7.55; 2.57) | 0.34 | -0.98 (-6.44; 4.48) | 0.73 | 0.15 (-5.00; 5.32) | 0.95 | ||
| Quality of life, utility (-0.29–1.00) | NA | NA | -0.01 (-0.06; 0.05) | 0.83 | -0.02 (-0.07; 0.03) | 0.44 | 0.01 (-0.05; 0.07) | 0.73 | -0.00 (-0.06; 0.05) | 0.92 | ||
| Anxiety and depressive disorder | 1.73 (0.69; 4.32) | 0.24 | 1.78 (0.66; 4.77) | 0.25 | 1.58 (0.66; 3.78) | 0.30 | 1.76 (0.71; 4.38) | 0.22 | 1.25 (0.51; 3.02) | 0.63 | 1.12 (0.42; 3.01) | 0.82 |
CI: confidence interval; DHI: Dizziness Handicap Inventory; VAS: visual analogue scale; OR: odds ratio; NA: not applicable
* Adjusted for age, sex, living alone, polypharmacy, dizziness onset, dizziness-related impairment, number of comorbidities, anxiety and depressive disorder, cardiovascular disease and functional mobility